Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/12/21 (What's New)

Summary

  • Recent investigations have studied newer agents as part of NRTI-sparing regimens in treatment-naive patients
  • The IAS-USA guidelines includes no NRTI-sparing as initial ART, but recognizes that they can produce comparable virological results as 3-drug regimens[IASUSA ART]
  • The DHHS guidelines now include dolutegravir/lamivudine as a recommended regimen for most people with HIV, except for individuals with HIV-1 RNA > 500,000 copies/mL, potential HBV coinfection, or those with no HIV genotype resistance testing results for reverse transcriptase

Action required

Keywords: Initial Antiretroviral Therapy

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.